You are Trying to View a Free Article
Daily News You Can't Find Anywhere ElseWuXi Biologics Authorizes Exelixis to Expand Oncology Biological Drug Production, an Industrial Info Market Brief
Industry Segment: Market Brief | Word Count: 72 Words
Attachment: A
WuXi Biologics has authorized Exelixis exclusively to expand its oncology biological drug production. WuXi AppTec, which includes WuXi Biologics, has 14 plants, with half in the U.S. and half in China.
WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.
Subscribe Now! All Fields Required...
Related Articles
- Central Asia Home For $762.8 Million in Glass Manufacturing Projects, an In...
- Central Asia Home For $762.8 Million in Glass Manufacturing Projects, an In...
- Algeria's Groupement TouatGaz Proceeds with Second-Phase Development, an In...
- Diamond Production in Africa to Increase in 2021, an Industrial Info Market...
- Europe Set for $240 Million in Pulp, Paper, Wood Maintenance through End of...
- Current Economic Indicators
- Free Daily Industrial Articles
- Monthly Industrial Newsletter
- IIR's Disaster Impact Tracker
All Members Receive the Following Free Resources:
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
